Fluconazole-Induced Thrombocytopenia
Authors: Anupam Agarwal
Journal: Annals of Internal Medicine (1990)

Letters1 December 1990Fluconazole-Induced ThrombocytopeniaAnupam Agarwal, MD, V. Sakhuja, MD, K.S. Chugh, MDAnupam Agarwal, MDSearch for more papers by this author, V. Sakhuja, MDSearch for more papers by this author, K.S. Chugh, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-11-899_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:Fluconazole, a new, effective, administered orally triazole antifungal agent (1), has been reported to be relatively free of serious side effects. Nausea, abdominal pain, asymptomatic elevation of liver enzymes, skin rash, and interaction with other drugs (for example, cyclosporin) have been documented (2, 3). In a recent study, Larsen and colleagues (4) observed thrombocytopenia (platelet count < 150 000/mm3) in both of their treatment groups (patients received either fluconazole or amphotericin B plus flucytosine) but did not associate it with study drug therapy. We report the case of a patient with disseminated cryptococcosis who was receiving fluconazole...References1. Galgiani J. Fluconazole, a new antifungal agent. Editorial. Ann Intern Med. 1990;113:177-9. LinkGoogle Scholar2. Saag M and Dismukes W. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988;32:1-8. CrossrefMedlineGoogle Scholar3. Sugar A, Saunders C, Idelson B, and Bernard D. Interaction of fluconazole and cyclosporine. Ann Intern Med. 1989;110:844. LinkGoogle Scholar4. Larsen R, Leal M, and Chan L. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med. 1990;113:183-7. LinkGoogle Scholar5. Sugar A and Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988;85:481-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Anupam Agarwal, MD; V. Sakhuja, MD; K.S. Chugh, MDAffiliations: Postgraduate Institute of Medical Education and Research Chandigarh-160012 India PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFluconazole associated agranulocytosis and thrombocytopeniaRifabutin-Induced Thrombocytopenia from Concurrent Use of High-Dose FluconazoleFluconazoleThrombocytosis During Antifungal Therapy of CandidemiaThe life-threatening complications of dermatologic therapiesNew agents for the treatment of systemic fungal infections – current statusSYSTEMIC ANTIFUNGAL THERAPYNew agents for treatment of systemic fungal infectionsAdverse drug reactions of the new oral antifungal agents – terbinafine, fluconazole, and itraconazoleThrombocytopenia in Intensive Care Patients: A Comprehensive Analysis of Risk Factors in 314 PatientsThrombocytopenia caused by fluconazole therapyFungal Infections in the Immunocompromised HostRisk/benefit ratio of modern antifungal therapy: Focus on hepatic reactionsAgranulocytosis during Treatment with FluconazoleHIV-Related Infections of the Oral CavityA Continuous Ambulatory Peritoneal Dialysis Patient With Fungal Peritonitis 1 December 1990Volume 113, Issue 11Page: 899-899KeywordsCryptococcosisDrug interactionsDrug therapyDrugsEnzymesLiverNauseaPatientsPlateletsRashes ePublished: 1 December 2008 Issue Published: 1 December 1990 PDF downloadLoading ...